Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Turk J Gastroenterol
October 2022
Department of Gastroenterology, Ankara City Hospital, Ankara, Turkey.
Background: Vedolizumab, which is a monoclonal antibody that selectively binds to α4β7 integrin in the gastrointestinal system, may be an effective and safe treatment alternative in those with anti-tumor necrosis factor-resistant inflammatory bowel disease.
Methods: Patients administered vedolizumab due to anti-tumor necrosis factor resistant or anti-tumor necrosis factor side effects between August 2017 and November 2020 were included in the study. Crohn's patients were evaluated using the Harvey-Bradshaw index and Simple Endoscopic Score for Crohn's Disease, whereas ulcerative colitis patients were evaluated with the Partial Mayo Score Index and Rachmilewitz score.
Erythrocyte Autoantibody Positivity in Serological Cross-matching.
J Coll Physicians Surg Pak
May 2020
Faculty of Medicine, Department of Anesthesiology and Reanimation, Balıkesir University, Turkey.
Objective: To investigate the erythrocyte autoantibody positivity detected in the serological cross-matching (XM), and its possible effects on salient hemogram parameters.
Study Design: A descriptive study.
Place And Duration Of Study: Balıkesir Atatürk City Hospital's Blood Transfusion Centre, Faculty of Medicine, Department of Anesthesiology and Reanimation, Balıkesir University, Turkey, from 2017 to 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!